Groll, Andreas H.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 1,556

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityOcular Infections and Treatments

Cited by 1,217

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 682

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R. (2002) · The Pediatric Infectious Disease Journal

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 431

ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.

Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 386

Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 377

ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 360

ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 334

Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis

Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityPharmaceutical studies and practices

Cited by 123

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and Efficacy

Cited by 93

Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Verbruggen, L. C., Wang, Y., Armenian, S. H., Ehrhardt, M. J., van der Pal, H. J. H., van Dalen, E. C., van As, J. W., Bardi, E., Baust, K., Berger, C., et al. (2020) · Pediatric Blood & Cancer

Childhood Cancer Survivors' Quality of LifeCOVID-19 and healthcare impacts

Cited by 31

Diagnostic Approaches for Invasive Aspergillosis—Specific Considerations in the Pediatric Population

Lehrnbecher, T., Hassler, A., Groll, A. H., & Bochennek, K. (2018) · Frontiers in Microbiology

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 29